ILMN - Illumina, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
319.58
-7.42 (-2.27%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close327.00
Open327.72
Bid319.00 x 1000
Ask326.50 x 900
Day's Range318.34 - 328.31
52 Week Range263.30 - 380.76
Volume972,699
Avg. Volume962,296
Market Cap46.978B
Beta (5Y Monthly)1.04
PE Ratio (TTM)48.90
EPS (TTM)6.53
Earnings DateJan 28, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est345.56
  • Can Sequencing Products Aid Illumina (ILMN) in Q4 Earnings?
    Zacks

    Can Sequencing Products Aid Illumina (ILMN) in Q4 Earnings?

    Illumina (ILMN) is upbeat about fourth-quarter and fiscal 2019 results after a strong third-quarter performance.

  • 23andMe cuts 100 jobs as demand for DNA tests drops
    American City Business Journals

    23andMe cuts 100 jobs as demand for DNA tests drops

    CEO Anne Wojcicki said that she is surprised by declining demand for her Sunnyvale company's genetic tests.

  • Illumina (ILMN) Reports Next Week: Wall Street Expects Earnings Growth
    Zacks

    Illumina (ILMN) Reports Next Week: Wall Street Expects Earnings Growth

    Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • 4 High-Quality Health Care Companies for 2020
    GuruFocus.com

    4 High-Quality Health Care Companies for 2020

    Stocks to consider as China agrees to purchase $200 billion in US goods, including pharma Continue reading...

  • Business Wire

    Illumina to Announce Fourth Quarter and Fiscal Year 2019 Financial Results on Wednesday, January 29, 2020

    Illumina to Announce Fourth Quarter and Fiscal Year 2019 Financial Results

  • Illumina News: ILMN Stock 4% Lower on Weak 2020 Outlook
    InvestorPlace

    Illumina News: ILMN Stock 4% Lower on Weak 2020 Outlook

    Illumina (NASDAQ:ILMN) news for Monday includes ILMN stock falling on a weak outlook for 2020.Source: Shutterstock The negative Illumina news comes directly from CEO Francis deSouza. During a presentation at the JPMorgan Healthcare Conference, he said that 2020 revenue growth is expected to come in between 9% and 11%.The bad Illumina news here is that Wall Street is expecting stronger revenue growth for the full year of 2020. To be more clear, analysts are looking for ILMN's revenue growth to reach 12% in 2020, reports SeekingAlpha.InvestorPlace - Stock Market News, Stock Advice & Trading TipsIllumina's poor outlook for 2020 isn't the only recent news for the company. It also announced today that it has signed a 15-year deal with Roche Partner. This deal is non-exclusive and will focus on increasing the adoption of distributable next-generation sequencing-based testing in oncology.The deal will have Roche Partner developing, manufacturing and commercializing "AVENIO IVD tests for both tissue and blood for use on Illumina's NextSeq 550Dx System." * 7 Inflation-Beating REITs to Ground Your Income Portfolio Omead Ostadan, Senior Vice President of Marketing and Products at Illumina, says this about the ILMN stock news."We are proud to continue our tradition of driving down the cost of sequencing without compromising accuracy. NextSeq 1000 and 2000 are designed to enable core labs, small to medium research labs and clinical facilities to access high intensity sequencing applications using our industry-leading SBS technology."ILMN stock was down 4.04% as of Monday afternoon.As of this writing, William White did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Inflation-Beating REITs to Ground Your Income Portfolio * 7 Healthcare Stocks to Buy or Sell As Pricing Pressures Mount * 7 Earnings Reports to Watch This Week The post Illumina News: ILMN Stock 4% Lower on Weak 2020 Outlook appeared first on InvestorPlace.

  • Business Wire

    Illumina Announces New Sequencing System, Partnership with Roche and Software Suite to Accelerate Adoption of Genomics

    Illumina, Inc. (NASDAQ: ILMN) further demonstrated its commitment to making genomics more accessible for the potential benefit of patients today with a series of technology and partnership announcements that further the company’s commitment to unlocking the power of the genome.

  • Business Wire

    Illumina and Roche Partner to Broaden Patient Access to Genomic Testing

    Illumina, Inc. (NASDAQ: ILMN), the global leader in DNA sequencing and array-based technologies, and Roche, a global pioneer in pharmaceuticals and diagnostics, today announced a 15-year, non-exclusive collaboration agreement to broaden the adoption of distributable next-generation sequencing-based (NGS) testing in oncology. As the understanding of genomic drivers of cancer evolves, NGS has the potential to transform cancer risk prediction, detection, diagnosis, treatment and monitoring.

  • Business Wire

    Illumina Files Patent Infringement Suits Against BGI in Sweden and the United Kingdom

    Illumina Files Patent Infringement Suits Against BGI in Sweden and the United Kingdom

  • ArcherDX and Illumina Partner for Future to Co-Market Portfolio of Planned In-Vitro Diagnostic (IVD) Tests
    PR Newswire

    ArcherDX and Illumina Partner for Future to Co-Market Portfolio of Planned In-Vitro Diagnostic (IVD) Tests

    ArcherDX, Inc. today announced a non-exclusive, multi-year partnership with Illumina, Inc. (NASDAQ: ILMN) intended to broaden access of next generation sequencing (NGS)-based oncology testing, including companion diagnostics for therapeutic selection, personalized monitoring, and recurrence surveillance IVD tests, upon FDA approval, enabling more patient access to world-class care in their own community, delivered by local clinicians.

  • EBS vs. ILMN: Which Stock Is the Better Value Option?
    Zacks

    EBS vs. ILMN: Which Stock Is the Better Value Option?

    EBS vs. ILMN: Which Stock Is the Better Value Option?

  • Why Illumina (ILMN) is Poised to Beat Earnings Estimates Again
    Zacks

    Why Illumina (ILMN) is Poised to Beat Earnings Estimates Again

    Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

  • ETF Trends

    Illumina Stock Could Illuminate This Healthcare ETF

    Biotech firm Illumina, Inc. (ILMN) scrapped a merger with Pacific Biosciences, but there's still a lot to like about Illumina and for investors that can't handle the stock's over $300 price tag, the ARK Genomic Revolution Multi-Sector Fund (ARKG) is an adequate proxy on the stock. ARKG allocates 10.38% of its weight to shares of Illumina, making it the ETF with the largest weight to that stock. ARKG's stablemate, the   ARK Innovation ETF (ARKK) , is second with an Illumina weight of about 7%.

  • Why Illumina, Inc. (NASDAQ:ILMN) Could Be Worth Watching
    Simply Wall St.

    Why Illumina, Inc. (NASDAQ:ILMN) Could Be Worth Watching

    Illumina, Inc. (NASDAQ:ILMN) saw a double-digit share price rise of over 10% in the past couple of months on the...

  • Sequencing giant Illumina scraps $1.2 billion PacBio acquisition
    American City Business Journals

    Sequencing giant Illumina scraps $1.2 billion PacBio acquisition

    Genetic sequencing giant Illumina Inc. has nixed its $1.2 billion acquisition attempt of Menlo Park's Pacific Biosciences amid intense regulator scrutiny. San Diego-based Illumina announced the all-cash deal to purchase its smaller competitor in 2018, but it has faced an uphill battle to convince regulators in the U.S. and Europe. In October, antitrust regulators in the UK put out a statement of concern about the proposed merger given Illumina's immense market power in the highly-concentrated DNA sequencing industry.

  • Illumina Stock Slips on Pacific Biosciences Deal Termination
    Zacks

    Illumina Stock Slips on Pacific Biosciences Deal Termination

    Per Illumina (ILMN), the lengthy route to achieve regulatory nods for the transaction induces uncertainty about the ultimate outcome of the integration.

  • Barrons.com

    Illumina and Pacific Biosciences Call the Merger Off. Shares Barely React.

    The two companies, which both sell DNA sequencing tools, announced on Thursday that they had decided to cancel their proposed merger.

  • Benzinga

    The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 2) Agile Therapeutics Inc (NASDAQ: AGRX (announced the ...

  • TheStreet.com

    U.S. Kills Iranian General, Oil Prices Surge, FOMC to Release Minutes - 5 Things You Must Know Friday

    U.S. stock futures sink and oil prices surge after a U.S. military strike kills Gen. Qassem Soleimani, a top Iranian general; the U.S. economic calendar includes the ISM Manufacturing Index for December and minutes from the Federal Reserve's Dec. 10-11 meeting; Illumina abandons $1.2 billion acquisition of Pacific Biosciences.

  • Illumina and Pacific Biosciences Call Off $1.2 Billion Deal
    Bloomberg

    Illumina and Pacific Biosciences Call Off $1.2 Billion Deal

    (Bloomberg) -- Illumina Inc. and Pacific Biosciences of California Inc. called off their planned $1.2 billion deal after U.S. antitrust enforcers last month moved to block the merger of the DNA-sequencing companies.The transaction had been on hold for more than a year after being announced in November 2018. But antitrust authorities in the U.S. and the U.K. had pushed back against it, and the U.S. Federal Trade Commission filed a complaint to block it last month.“Considering the lengthy regulatory approval process the transaction has already been subject to and continued uncertainty of the ultimate outcome, the parties decided that terminating the agreement” was the best option, the companies said in a joint statement Thursday.Both companies make DNA sequencing machines, a fast-growing segment of the biotechnology and medical sectors driven by demand from drugmakers, hospitals and research institutions. Illumina will pay Pacific Biosciences a $98 million termination fee.Shares of Menlo Park, California-based Pacific Biosciences gained 3.5% to $5.34 per share in New York trading after the markets closed; the stock had been trading well below the deal’s $8-a-share value. Illumina shares were unchanged.Gail Levine, deputy director of the FTC’s Bureau of Competition, said in a statement Thursday that calling off the deal would preserve a more vibrant market.“This deal threatened to let a monopolist extinguish nascent competition in a growing health care market: next-generation DNA sequencing. Customers across the United States and the world will now continue to benefit from the independent innovative efforts of these companies to develop faster, better, and less expensive next-generation DNA sequencing technologies,” Levine said.Her remarks echoed comments in December when the commission moved to block the transaction. And Illumina said at the time it would keep working to get the deal through while examining its options. “It is not clear that we will be able to secure the required regulatory approvals to allow this transaction to close,” Illumina spokesman Eric Endicott said in an email Thursday. “We believe it is in the best interest of both companies’ shareholders and employees to terminate this agreement now.”One recent analysis by Morningstar Inc. estimated that Illumina controls more that 70% of the market for sequencing the human genome. Its DNA-sequencing machines range from bench-top devices to high-end sequencers that can cost as much as $1 million each, and are used in drug discovery, medicine, biological research and consumer testing.Pacific Biosciences’s machines use a different type of technology, which can decode extensive stretches of DNA with a high degree of accuracy. Unlike the technology Illumina’s machines use, it can read some particularly difficult-to-analyze circumstances. At the time the deal was announced, Illumina said the takeover could help lower the cost of long-read sequencing from $12,000 to $1,000.(Updates Pacific Biosciences shares in the fifth paragraph)\--With assistance from David McLaughlin.To contact the reporter on this story: Kristen V. Brown in San Francisco at kbrown340@bloomberg.netTo contact the editors responsible for this story: Drew Armstrong at darmstrong17@bloomberg.net, Timothy AnnettFor more articles like this, please visit us at bloomberg.com©2020 Bloomberg L.P.

  • MarketWatch

    Illumina, Pacific Biosciences drop $1.2 billion merger agreement

    Illumina Inc. and Pacific Biosciences of California Inc. on Thursday said they have agreed to drop plans to merge. Under the merger agreement, announced Nov. 1, Illumina would have paid $1.2 billion in cash for Pacific Biosciences. The news sent Pacific Biosciences shares down 3% in after-hours trading. The lengthy regulatory approval process required for the transaction "has already been subject to and continued uncertainty of the ultimate outcome," the companies said in a joint news release. As part of the merger agreement, Illumina will pay Pacific Biosciences a termination fee of $98 million. The announcement was made after markets closed.

  • Business Wire

    Illumina and Pacific Biosciences Announce Termination of Merger Agreement

    Illumina, Inc. (NASDAQ:ILMN) and Pacific Biosciences of California, Inc. (NASDAQ:PACB) today announced that they have mutually agreed to terminate their merger agreement, previously announced on November 1, 2018, under which Illumina would acquire Pacific Biosciences at a fully diluted enterprise value of approximately $1.2 billion in an all-cash transaction.

  • Here's Why You Should Retain Pacific Biosciences Stock Now
    Zacks

    Here's Why You Should Retain Pacific Biosciences Stock Now

    Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, stiff competition remains a woe.

  • Hedge Fund Favorites vs. Illumina, Inc. (ILMN) In 2019
    Insider Monkey

    Hedge Fund Favorites vs. Illumina, Inc. (ILMN) In 2019

    It has been a fantastic year for equity investors as Donald Trump pressured Federal Reserve to reduce interest rates and finalized the first leg of a trade deal with China. If you were a passive index fund investor, you had seen gains of 31% in your equity portfolio in 2019. However, if you were an […]